Skip to content

Study · Case report or series · n = 1 · 2025

7 results

Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report.

Dinoi E, Daniele G, Michelucci A, Baldinotti F, Campi F, Marchetti P, Del Prato S, Dardano A

Frontiers in endocrinology10 Feb 2025Cited by 1 (Europe PMC)

PMID39996062 (opens in a new tab)PMCIDPMC11847660 (opens in a new tab)DOI10.3389/fendo.2025.1533209 (opens in a new tab)PepBankPUB-39996062
Download PDFPubMedAsk about this study
Jump to 7 results

Summary

BackgroundThe treatment of obesity and type 2 diabetes (T2D) in Prader-Willi syndrome (PWS) is still a challenge. Glucagon-like peptide 1 receptor agonists (GLP-1 RA) are attractive options, since they effectively reduce weight and improve blood glucose, without increasing the risk of hypoglycemia. However, data on their use in PWS are scarce.Case descriptionIn 2019, a 27-year-old male came to our Clinic because of first appearance of severe hyperglycemia (fasting plasma glucose 22.5 mmol/L). Based on clinical presentation, PWS was suspected, and diagnosis was confirmed by genetic tests. The patient was discharged on a basal-bolus insulin therapy managed by his parents due to his cognitive impairment. In spite of COVID-19 pandemic, the patient achieved tight glycemic control (HbA1c 41 mmol/mol) with non-severe hypoglycemic events in the face of significant body weight (BW) increase (+ 13 kg vs baseline). Insulin therapy was then discontinued, and once-weekly semaglutide (up to 0,5 mg weekly) was started. At 12-month follow-up, BW dropped from 79 to 73 kg while maintaining excellent glycemic control (HbA1c 40 mmol/mol). At 24-month follow-up, glycemic control remained optimal (HbA1c 38 mmol/mol) with further BW reduction (71 kg). Neither hypoglycemia nor gastro-intestinal or psychiatric adverse events were reported.ConclusionThis case supports the potential use of semaglutide for the treatment of subjects with PWS, obesity and T2D. Ad hoc trials are needed to evaluate the long-term efficacy and tolerability in these subjects.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a young man with Prader-Willi syndrome, obesity and type 2 diabetes, body weight fell from 79 to 73 kg after 12 months of once-weekly semaglutide.

    In plain wordsIn one young man with Prader-Willi syndrome and diabetes, weight fell from 79 to 73 kg after 12 months of semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight at 12 months
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    up to 0.5 mg weekly · 24 monthsAs given in this study (human).

    Measurements

    Body weight
    79 kg
    baseline
    Body weight
    73 kg
    12 months

    Source sentences

    Summary
    At 12-month follow-up, BW dropped from 79 to 73 kg
    2 context sentences
    Summary · context
    In 2019, a 27-year-old male came to our Clinic because of first appearance of severe hyperglycemia (fasting plasma glucose 22.5 mmol/L).
    Summary · context
    Insulin therapy was then discontinued, and once-weekly semaglutide (up to 0,5 mg weekly) was started.
  2. 02HumanCase report or seriesEfficacy outcome

    In a young man with Prader-Willi syndrome, obesity and type 2 diabetes, excellent glycemic control was maintained at 12 months on semaglutide (HbA1c 40 mmol/mol).

    In plain wordsIn one young man with Prader-Willi syndrome and diabetes, blood sugar control stayed excellent after 12 months of semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeHbA1c at 12 months
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    up to 0.5 mg weekly · 24 monthsAs given in this study (human).

    Measurements

    HbA1c
    40 mmol/mol
    12 months

    Source sentences

    Summary
    while maintaining excellent glycemic control (HbA1c 40 mmol/mol)
    2 context sentences
    Summary · context
    In 2019, a 27-year-old male came to our Clinic because of first appearance of severe hyperglycemia (fasting plasma glucose 22.5 mmol/L).
    Summary · context
    Insulin therapy was then discontinued, and once-weekly semaglutide (up to 0,5 mg weekly) was started.
  3. 03HumanCase report or seriesEfficacy outcome

    In a young man with Prader-Willi syndrome, obesity and type 2 diabetes, body weight fell further to 71 kg at 24 months of semaglutide.

    In plain wordsIn one young man with Prader-Willi syndrome and diabetes, weight fell further to 71 kg after 24 months of semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight at 24 months
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    up to 0.5 mg weekly · 24 monthsAs given in this study (human).

    Measurements

    Body weight
    71 kg
    24 months

    Source sentences

    Summary
    with further BW reduction (71 kg)
    2 context sentences
    Summary · context
    In 2019, a 27-year-old male came to our Clinic because of first appearance of severe hyperglycemia (fasting plasma glucose 22.5 mmol/L).
    Summary · context
    Insulin therapy was then discontinued, and once-weekly semaglutide (up to 0,5 mg weekly) was started.
  4. 04HumanCase report or seriesEfficacy outcome

    In a young man with Prader-Willi syndrome, obesity and type 2 diabetes, glycemic control remained optimal at 24 months on semaglutide (HbA1c 38 mmol/mol).

    In plain wordsIn one young man with Prader-Willi syndrome and diabetes, blood sugar control stayed optimal after 24 months of semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeHbA1c at 24 months
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    up to 0.5 mg weekly · 24 monthsAs given in this study (human).

    Measurements

    HbA1c
    38 mmol/mol
    24 months

    Source sentences

    Summary
    At 24-month follow-up, glycemic control remained optimal (HbA1c 38 mmol/mol)
    2 context sentences
    Summary · context
    In 2019, a 27-year-old male came to our Clinic because of first appearance of severe hyperglycemia (fasting plasma glucose 22.5 mmol/L).
    Summary · context
    Insulin therapy was then discontinued, and once-weekly semaglutide (up to 0,5 mg weekly) was started.
  5. 05HumanCase report or seriesSafety outcome

    In a young man with Prader-Willi syndrome, no hypoglycemia was reported on semaglutide.

    In plain wordsIn one young man with Prader-Willi syndrome and diabetes, no low blood sugar was reported on semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeHypoglycemia
    Study

    n = 1

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    up to 0.5 mg weekly · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Neither hypoglycemia nor gastro-intestinal or psychiatric adverse events were reported.
    2 context sentences
    Summary · context
    In 2019, a 27-year-old male came to our Clinic because of first appearance of severe hyperglycemia (fasting plasma glucose 22.5 mmol/L).
    Summary · context
    Insulin therapy was then discontinued, and once-weekly semaglutide (up to 0,5 mg weekly) was started.
  6. 06HumanCase report or seriesSafety outcome

    In a young man with Prader-Willi syndrome, no gastrointestinal adverse events were reported on semaglutide.

    In plain wordsIn one young man with Prader-Willi syndrome and diabetes, no stomach or gut side effects were reported on semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeGastrointestinal adverse events
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    up to 0.5 mg weekly · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Neither hypoglycemia nor gastro-intestinal or psychiatric adverse events were reported.
    2 context sentences
    Summary · context
    In 2019, a 27-year-old male came to our Clinic because of first appearance of severe hyperglycemia (fasting plasma glucose 22.5 mmol/L).
    Summary · context
    Insulin therapy was then discontinued, and once-weekly semaglutide (up to 0,5 mg weekly) was started.
  7. 07HumanCase report or seriesSafety outcome

    In a young man with Prader-Willi syndrome, no psychiatric adverse events were reported on semaglutide.

    In plain wordsIn one young man with Prader-Willi syndrome and diabetes, no mental health side effects were reported on semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changePsychiatric adverse events
    Study

    n = 1

    Outcome group
    Adverse events · Mental health and mood
    Studied dose
    up to 0.5 mg weekly · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Neither hypoglycemia nor gastro-intestinal or psychiatric adverse events were reported.
    2 context sentences
    Summary · context
    In 2019, a 27-year-old male came to our Clinic because of first appearance of severe hyperglycemia (fasting plasma glucose 22.5 mmol/L).
    Summary · context
    Insulin therapy was then discontinued, and once-weekly semaglutide (up to 0,5 mg weekly) was started.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.